Targeted molecular therapy for neuroblastoma: the ARF/MDM2/p53 axis

J Natl Cancer Inst. 2009 Nov 18;101(22):1527-9. doi: 10.1093/jnci/djp376. Epub 2009 Nov 10.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Cyclin-Dependent Kinase Inhibitor p16 / antagonists & inhibitors*
  • Humans
  • Imidazoles / pharmacology*
  • Imidazoles / therapeutic use
  • Mice
  • Mice, Transgenic
  • N-Myc Proto-Oncogene Protein
  • Neuroblastoma / drug therapy*
  • Neuroblastoma / genetics
  • Neuroblastoma / metabolism
  • Nuclear Proteins / antagonists & inhibitors*
  • Oncogene Proteins / antagonists & inhibitors*
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use
  • Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors*
  • Transcriptional Activation / drug effects
  • Tumor Suppressor Protein p53 / drug effects*
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Antineoplastic Agents
  • Cdkn2a protein, mouse
  • Cyclin-Dependent Kinase Inhibitor p16
  • Imidazoles
  • MYCN protein, human
  • N-Myc Proto-Oncogene Protein
  • Nuclear Proteins
  • Oncogene Proteins
  • Piperazines
  • Tumor Suppressor Protein p53
  • nutlin 3
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2